解析重离子如何治疗肿瘤

2018-01-04 帅才、梁军 新华社

重离子疗法从三方面对肿瘤产生作用。

专家指出,未来,多学科融合治疗肿瘤将成为大势所趋。随着生物学、材料学、人文医学等学科的发展,多学科综合诊治肿瘤将成为大势所趋。

湖南省人民医院副院长向华教授指出,多学科治疗肿瘤能最大限度避免局部治疗的弊端和疏漏,优化出最适合患者的方案,对病情复杂患者的诊疗效果更为明显。

向华说,介入治疗近年来发展迅速,可作为肿瘤手术前的辅助治疗,也可以作为术后预防复发和转移的治疗。随着新药物、新材料等不断研发,当前介入治疗术已涉及全身各个器官,适用于颅脑、肺、肝、胆等的灌注化疗和栓塞、肿瘤等。据介绍,目前,肿瘤微创介入包括热消融、冷消融以及化学消融等方法。对于肝癌患者可以实施微创介入手术。

向华告诉记者,介入医生通过患者大腿处1毫米的针眼插入肝动脉一根极细的导管,注入造影剂,使肝癌染色显影,再经导管引入一条更细的微导管,插进肿瘤血管,注入栓塞剂,遏制住肝脏血供使肿瘤缺乏营养而“饿死”。可以通过栓塞疗法,用药物把肿瘤周围的血管灌注堵塞,经过治疗,使患者的肿瘤因缺乏营养而活活饿死;还可以采用零下135摄氏度的低温冷冻治疗,把肿瘤给“冻死”。

重离子治疗肿瘤是目前各国研究的高精尖技术热点,也是公认的先进有效的治疗肿瘤方法。中科院近代物理研究所所长肖国青说,临床试验表明,重离子治疗对肺癌、肝癌乃至医学界最头疼的黑色素瘤等恶性肿瘤的局部控制率达80%以上。中科院在此方面已做了多年探索,联合甘肃省武威和兰州两市,先后打造集肿瘤诊断、治疗、康复等为一体的武威重离子治疗示范中心和兰州重离子治疗示范中心。

肖国青说,我国自主研制的重离子治疗癌症技术已获得突破性进展,临床试验表明重离子治疗癌症效果明显,目前已经具备临床推广条件。对于患者来说,与传统的放射治疗肿瘤的电子、X等常规射线相比,重离子束具有对健康组织辐射损伤轻、疗程短、控制率高等特点。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1650630, encodeId=13071650630ce, content=<a href='/topic/show?id=844c96012df' target=_blank style='color:#2F92EE;'>#重离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96012, encryptionId=844c96012df, topicName=重离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2824060557, createdName=jj000009, createdTime=Tue Nov 13 04:36:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672874, encodeId=213e16e287434, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sun Sep 02 11:36:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278806, encodeId=ab432e8806e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 15 19:11:01 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275449, encodeId=abb12e544993, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Jan 04 18:12:13 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1650630, encodeId=13071650630ce, content=<a href='/topic/show?id=844c96012df' target=_blank style='color:#2F92EE;'>#重离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96012, encryptionId=844c96012df, topicName=重离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2824060557, createdName=jj000009, createdTime=Tue Nov 13 04:36:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672874, encodeId=213e16e287434, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sun Sep 02 11:36:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278806, encodeId=ab432e8806e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 15 19:11:01 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275449, encodeId=abb12e544993, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Jan 04 18:12:13 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-09-02 hongbochen
  3. [GetPortalCommentsPageByObjectIdResponse(id=1650630, encodeId=13071650630ce, content=<a href='/topic/show?id=844c96012df' target=_blank style='color:#2F92EE;'>#重离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96012, encryptionId=844c96012df, topicName=重离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2824060557, createdName=jj000009, createdTime=Tue Nov 13 04:36:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672874, encodeId=213e16e287434, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sun Sep 02 11:36:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278806, encodeId=ab432e8806e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 15 19:11:01 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275449, encodeId=abb12e544993, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Jan 04 18:12:13 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-01-15 杨柳青青

    签到学习了--

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1650630, encodeId=13071650630ce, content=<a href='/topic/show?id=844c96012df' target=_blank style='color:#2F92EE;'>#重离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96012, encryptionId=844c96012df, topicName=重离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f2824060557, createdName=jj000009, createdTime=Tue Nov 13 04:36:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672874, encodeId=213e16e287434, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Sun Sep 02 11:36:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278806, encodeId=ab432e8806e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 15 19:11:01 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275449, encodeId=abb12e544993, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Jan 04 18:12:13 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-01-04 Y—xianghai

    学习了新知识

    0

相关资讯

我国首台重离子治癌装置将投入临床

日前,甘肃重离子医院在武威召开临床试验方案研讨会。中、德、日三国放疗专家、物理师以及中科院近代物理研究所科研人员共同参会,研讨重离子治疗肿瘤临床试验方案。甘肃重离子医院表示,重离子治癌临床试验计划今年10月开始。 甘肃重离子医院院长叶延程介绍,目前医院各种设备和配套设施已到位,重离子专用装置正在进行检测测试,计划年底投入运营。 即将投入使用的医用重离子加速器由中科院近物所研发,是我

PTCOG 2014:质子重离子治疗肿瘤对话中外专家

本报上海6月12日(记者陈婕)在6月11日举行的媒体见面会上,第53届国际粒子肿瘤放射治疗大会主席蒋国梁教授和国际粒子肿瘤放射治疗组织主席尤金·B·霍克(Eugen B.Hug)教授共同接受了媒体记者的采访,解答了专业人士和公众感兴趣的质子重离子治疗肿瘤的热点问题。 Q1:如何选择适于质子重离子治疗的患者? Hug教授:理论上而言,质子重离子治疗适合所有可以接受光子治疗(传统放疗)的

上海市委书记出席开业仪式 这家医院何等了得

5月8日,上海市委书记韩正出席一家医院的开业仪式——上海市质子重离子医院暨复旦大学附属肿瘤医院质子重离子中心。名称中彰显浓厚特殊味道的这家医院,究竟有何特殊?独树一帜公开资料显示,运用质子或重离子射线治疗肿瘤,是目前国际公认的最尖端放射治疗技术。该技术也因杀癌效果好和毒副作用小而被誉为“治癌利器”。顾名思义,上海市质子重离子医院便是以这种国际尖端肿瘤放射治疗技术为主要治疗手段的现代化、国际化肿瘤中